Viking Therapeutics Faces Range-Bound Trading as VK-2735 Trials Progress | The 4 Pillar Report

Viking Therapeutics Faces Range-Bound Trading as VK-2735 Trials Progress

Viking Therapeutics remains neutral in its stock strategy as VK-2735 attempts to navigate mechanical headwinds following a 42% stock drop, despite aggressive growth projections. Without clear catalysts to justify the optimistic revenue expectations, potential upside may remain limited until phase III trial results are released, which are critical for reassessing market sentiment.

Week 14

Viking Therapeutics Faces Range-Bound Trading as VK-2735 Trials Progress

PILLAR DIAGNOSTIC // WEEK 14

Confidence 60%

“Aggressive growth expectations for VK-2735 are running into mechanical headwinds from recent distribution after the 42% plunge, and with no tangible map catalysts yet to validate lofty revenue projections, price action is likely to stay range-bound until positive phase III readouts force a broader sentiment re-rating.”

Proposed action

Neutral—avoid initiating new positions and consider trimming on rallies

THE MECHANICS

Tape & flow

-0.20

Viking Therapeutics stock saw a 42% collapse on August 19, 2025 upon mid-stage trial readout, while positioning has built anticipation for potential upside as phase three results and FDA approval approach.

THE MACHINE

Operational momentum

+0.74

VK2735 is advancing through phase 3 in both subcutaneous and oral forms, with patient enrollment completed in the VANQUISH-2 subcutaneous trial and oral phase III set to begin in Q3 2026; upon approval, the therapy is projected to drive billions in obesity-treatment revenues.

THE MAP

Structure & constraints

+0.00

VKTX is entering the dual GLP-1/GIP weight-loss drug segment with VK-2735.

THE MOOD

Consensus & positioning

+0.65

Investors are highly optimistic about VKTX’s obesity pipeline, viewing its maintenance trial and CEO credibility as key catalysts and anticipating best-in-class dual-agonist efficacy that could justify a massive premium despite past tolerability hiccups and lingering valuation gaps.

Week 14

Confidence: 60%

Aggressive growth expectations for VK-2735 are running into mechanical headwinds from recent distribution after the 42% plunge, and with no tangible map catalysts yet to validate lofty revenue projections, price action is likely to stay range-bound until positive phase III readouts force a broader sentiment re-rating.

Sentiment divergence signals

1 signal active

Value trap

MACMCH

Mechanics

Tape & flow

Viking Therapeutics stock saw a 42% collapse on August 19, 2025 upon mid-stage trial readout, while positioning has built anticipation for potential upside as phase three results and FDA approval approach.

Audit trail active

Machine

Operational momentum

VK2735 is advancing through phase 3 in both subcutaneous and oral forms, with patient enrollment completed in the VANQUISH-2 subcutaneous trial and oral phase III set to begin in Q3 2026; upon approval, the therapy is projected to drive billions in obesity-treatment revenues.

Audit trail active

The Map

Structure & constraints

VKTX is entering the dual GLP-1/GIP weight-loss drug segment with VK-2735.

Audit trail active

Mood

Consensus & positioning

Investors are highly optimistic about VKTX’s obesity pipeline, viewing its maintenance trial and CEO credibility as key catalysts and anticipating best-in-class dual-agonist efficacy that could justify a massive premium despite past tolerability hiccups and lingering valuation gaps.

Audit trail active